Brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will announce earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks. Five analysts have issued estimates for BioDelivery Sciences International’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.06). BioDelivery Sciences International posted earnings per share of ($0.18) in the same quarter last year, which would suggest a positive year over year growth rate of 55.6%. The business is scheduled to report its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.23) per share for the current financial year, with EPS estimates ranging from ($0.51) to ($0.12). For the next year, analysts expect that the business will report earnings of $0.18 per share, with EPS estimates ranging from $0.09 to $0.31. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10). BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. The business had revenue of $18.03 million during the quarter, compared to analysts’ expectations of $16.15 million.
In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $4.60, for a total transaction of $36,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $5.07, for a total transaction of $116,610.00. Following the sale, the director now directly owns 544,187 shares of the company’s stock, valued at $2,759,028.09. The disclosure for this sale can be found here. Insiders have sold a total of 2,048,050 shares of company stock valued at $10,241,990 over the last three months. Corporate insiders own 13.26% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in BDSI. Stonepine Capital Management LLC grew its stake in shares of BioDelivery Sciences International by 190.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 4,311,103 shares of the specialty pharmaceutical company’s stock valued at $12,071,000 after buying an additional 2,825,101 shares during the period. Nantahala Capital Management LLC grew its stake in shares of BioDelivery Sciences International by 64.0% during the 4th quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock valued at $10,114,000 after buying an additional 1,066,900 shares during the period. Point72 Asset Management L.P. grew its stake in shares of BioDelivery Sciences International by 150.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock valued at $4,200,000 after buying an additional 900,000 shares during the period. Millennium Management LLC grew its stake in shares of BioDelivery Sciences International by 703.6% during the 4th quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock valued at $3,631,000 after buying an additional 859,292 shares during the period. Finally, Pura Vida Investments LLC purchased a new stake in shares of BioDelivery Sciences International during the 4th quarter valued at $2,305,000. 57.09% of the stock is owned by institutional investors.
Shares of BDSI traded down $0.34 during mid-day trading on Friday, reaching $4.51. 30,244 shares of the company’s stock were exchanged, compared to its average volume of 1,096,591. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. BioDelivery Sciences International has a 52-week low of $1.70 and a 52-week high of $5.37. The stock has a market cap of $341.28 million, a price-to-earnings ratio of -6.18 and a beta of 0.46.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Further Reading: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.